CEACAM5 and neoplasm: [66] described development of two functional DNA aptamers chosen to bind the recombinant version of the IgV-like N domain of CEA and demonstrated its capability to prevent development of peritoneal tumor nodules from CEA-expressing tumor cells in vivo and disrupt CEA-mediated cellular interactions.